DHA Home About DHA Conferences Contact Us FOIA Site Map    
 

Clinical Operations /
Patient Care

Beneficiary Education and Support

TRICARE
Acquisitions

Financial
Operations

Information
Systems

Policy

Rates and
Reimbursement

Studies and
Evaluation

Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

TRICARE Management Activity Announcement:
DoD Medication Safety Notice: Varenicline (Chantix)

In light of recent reports linking Varenicline (Chantix) to hallucinations and even suicide, the Military Health System would like to re-issue our Medication Safety Notice concerning the use of Varenicline (Chantix), a prescription drug used across the country in smoking cessation programs. While the drug is not on the TRICARE formulary, many MHS patients have prescriptions for it. It is highly recommended that a doctor be consulted immediately in rare cases of psychiatric side effects including nightmares, paranoia, or feelings of suicide. In response to the recent FDA warnings, the Military Heath System is analyzing all available information in a continuing effort to maintain the highest levels of safety and security for our beneficiaries. For more information please refer to the DoD Medication Safety Notice issued by the Office of the Chief Medical Officer and the FDA’s Public Health Advisory on Chantix.

Sincerely,

Dr. S. Ward Casscells Assistant Secretary of Defense for Health Affairs